Aloperine

Cat. No.: HY-13516 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Aloperine is an alkaloid in sophora plants such as Sophora alopecuroides L, which has shown anti-cancer, anti-inflammatory and anti-virus properties. Aloperine is widely used to treat patients with allergic contact dermatitis eczema and other skin inflammation in China. Aloperine induces apoptosis and autophagy in HL-60 cells.

For research use only. We do not sell to patients.

Aloperine Chemical Structure

CAS No. : 56293-29-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

4 Publications Citing Use of MCE Aloperine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Filovirus Isoform Specific Products:

View All Isoforms

EBOV MARV ZEBOV

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Aloperine is an alkaloid in sophora plants such as Sophora alopecuroides L, which has shown anti-cancer, anti-inflammatory and anti-virus properties^[1]. Aloperine is widely used to treat patients with allergic contact dermatitis eczema and other skin inflammation in China^[2]. Aloperine induces apoptosis and autophagy in HL-60 cells^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK	CC₅₀	> 80 μM Compound: 1	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	CC₅₀	> 80 μM Compound: 1	Cytotoxicity in MDCK cells assessed as reduction of cell viability incubated for 2 days by CytoTox-Glo cytotoxicity assay Cytotoxicity in MDCK cells assessed as reduction of cell viability incubated for 2 days by CytoTox-Glo cytotoxicity assay	[PMID: 29152054]
MDCK	EC₅₀	14.5 μM Compound: 1	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MT4	CC₅₀	> 86 μM Compound: 1	Cytotoxicity in human MT4 cells assessed as reduction of cell viability incubated for 3 days by CytoTox-Glo cytotoxicity assay Cytotoxicity in human MT4 cells assessed as reduction of cell viability incubated for 3 days by CytoTox-Glo cytotoxicity assay	[PMID: 29152054]
MT4	CC₅₀	> 86.2 μM Compound: 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay	[PMID: 26985308]
MT4	EC₅₀	1.75 μM Compound: 1	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by Nano-Glo luciferase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by Nano-Glo luciferase reporter gene assay	[PMID: 26985308]

In Vitro

Aloperine (1-20 μM; 24 hours) gives growth-inhibitory IC₅₀ values in cancer cells ranges from 0.04 to 1.36 mM, the IC₅₀ values in HL-60, U937, K562, EC109, A549 and HepG2 cells are 0.04, 0.27, 0.36, 1.11, 1.18 and 1.36 mM,respectively^[1].
Aloperine (1-20 μM; 24 hours) induces apoptosis and decreases bcl-2 expression in HL-60 cells^[1].
Aloperine (20–100 μM; 18 hours) induces autophagy and formation of acidic vacuole in HL-60 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

232.37

Formula

C₁₅H₂₄N₂

CAS No.

56293-29-9

Appearance

Solid

Color

White to off-white

SMILES

[H][C@]1(C2)[C@](CCCC3)([H])N3C[C@]2([H])[C@@]4([H])C(CCCN4)=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 5.56 mg/mL (23.93 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3035 mL	21.5173 mL	43.0346 mL
5 mM	0.8607 mL	4.3035 mL	8.6069 mL
10 mM	0.4303 mL	2.1517 mL	4.3035 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (276 KB) SDS (392 KB)

COA (253 KB) HNMR (276 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Lin Z, et al. In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens Ait. Basic Clin Pharmacol Toxicol. 2011 May;108(5):304-9. [Content Brief]

[2]. Yuan XY, et al. Effects and mechanisms of aloperine on 2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice. Eur J Pharmacol. 2010 Mar 10;629(1-3):147-52. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.3035 mL	21.5173 mL	43.0346 mL	107.5866 mL
	5 mM	0.8607 mL	4.3035 mL	8.6069 mL	21.5173 mL
	10 mM	0.4303 mL	2.1517 mL	4.3035 mL	10.7587 mL
	15 mM	0.2869 mL	1.4345 mL	2.8690 mL	7.1724 mL
	20 mM	0.2152 mL	1.0759 mL	2.1517 mL	5.3793 mL

Aloperine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Aloperine56293-29-9ApoptosisAutophagyFilovirusHIVHuman immunodeficiency virusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Aloperine

Customer Review

Aloperine Related Antibodies

4 Publications Citing Use of MCE Aloperine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Filovirus Isoform Specific Products:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Aloperine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Aloperine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report